AstraZeneca (AZN) Stake: Capital Group Crosses 5.0096% (77.5M)

AstraZeneca PLC furnished a Form 6-K reporting a notification of major holdings showing that The Capital Group Companies, Inc. and its affiliated investment managers crossed the 5% ownership threshold on 20-Aug-2025.

Rhea-AI Filing Summary

AstraZeneca PLC furnished a Form 6-K reporting a notification of major holdings showing that The Capital Group Companies, Inc. and its affiliated investment managers crossed the 5% ownership threshold on 20-Aug-2025. The filing shows a resulting position of 77,500,852 shares, representing 5.009591% of voting rights, plus 14,685,540 depository receipts held indirectly (reported as 0.947037% indirect voting rights).

The disclosure explains the asset managers manage these shares on behalf of discretionary client accounts and that neither CGC nor its affiliates hold the shares for their own account. The Form 6-K is a routine, regulatory notification of significant institutional ownership rather than a corporate action by AstraZeneca.

Positive

• Disclosure compliance: The filing timely notifies a >5% institutional stake (crossed on 20-Aug-2025)
• Transparent ownership: 77,500,852 shares and 14,685,540 depository receipts are explicitly reported

Negative

• No adverse events reported; therefore no negative corporaterisk is disclosed in this filing

Insights

Institutional Ownership Analyst

Large passive stake disclosed: CGC holds just over 5% of AstraZeneca.

This filing confirms that The Capital Group Companies, Inc. and affiliated managers reached a 5.009591% voting stake via 77,500,852 shares on 20-Aug-2025. Such a threshold crossing must be disclosed under applicable rules and signals notable institutional interest.

Because the positions are held in discretionary client accounts, the filing indicates portfolio management activity rather than a strategic corporate influence by CGC.

Corporate Governance Analyst

Crossing the 5% mark may affect proxy visibility but not control.

Holding slightly above 5.00% can trigger greater attention in proxy contexts and engagement by the investor, though the stake remains minority and dispersed. The filing also reports 14,685,540 depository receipts counted as 0.947037% indirect voting rights, reflecting structure of ADR/DR holdings.

No board nominations, voting agreements, or changes to management were disclosed; this is a transparency filing rather than an activist move.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake did The Capital Group report in AstraZeneca (AZN)?

The filing reports 77,500,852 shares representing 5.009591% of voting rights, plus 14,685,540 depository receipts (reported as 0.947037% indirect voting rights).

When did Capital Group cross the 5% threshold in AZN?

The notification states the threshold was crossed on 20-Aug-2025.

Does the filing say Capital Group owns the shares for its own account?

No. The filing states the shares are owned by accounts under discretionary investment management of Capital Group entities, not by CGC for its own account.

Does this Form 6-K indicate any change in AstraZeneca’s management or strategy?

No. The Form 6-K is a holdings notification and does not disclose any corporate actions, management changes, or strategic decisions by AstraZeneca.

Are depository receipts included in the ownership percentage?

Yes. The filing lists 14,685,540 depository receipts contributing 0.947037% of indirect voting rights.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/21/2025 - 10:51 AM EDT Learn about SEC filing dates

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of August 2025

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Holding(s) in Company

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB0009895292

Issuer Name

ASTRAZENECA PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

The Capital Group Companies, Inc.

City of registered office (if applicable)

Los Angeles

Country of registered office (if applicable)

USA

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

City of registered office (if applicable)

Country of registered office (if applicable)

5. Date on which the threshold was crossed or reached

19-Aug-2025

6. Date on which Issuer notified

20-Aug-2025

7. Total 9. Information in relation to the person subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	4.997854	0.000000	4.997854	77500852
Position of previous notification (if applicable)	5.009591	0.000000	5.009591

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB0009895292 Common Stock		62815312		4.050817
US0463531089 Depository Receipt		14685540		0.947037
Sub Total 8.A	77500852		4.997854%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
The Capital Group Companies, Inc.	Capital Research and Management Company
The Capital Group Companies, Inc.	Capital International, Inc.
The Capital Group Companies, Inc.	Capital Group Private Client Services, Inc.
The Capital Group Companies, Inc.	Capital International Sarl
The Capital Group Companies, Inc.	Capital International Limited

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

The Capital Group Companies, Inc. ("CGC") is the parent company of Capital Research and Management Company ("CRMC") and Capital Bank & Trust Company ("CB&T"). CRMC is a U.S.-based investment management company that serves as investment manager to the American Funds family of mutual funds, other pooled investment vehicles, as well as individual and institutional clients. CRMC and its investment manager affiliates manage equity assets for various investment companies through three divisions, Capital Research Global Investors, Capital International Investors and Capital World Investors. CRMC is the parent company of Capital Group International, Inc. ("CGII"), which in turn is the parent company of six investment management companies ("CGII management companies"): Capital International, Inc., Capital International Limited, Capital International Sàrl, Capital International K.K., Capital Group Private Client Services Inc, and Capital Group Investment Management Private Limited. CGII management companies primarily serve as investment managers to institutional and high net worth clients. CB&T is a U.S.-based registered investment adviser and an affiliated federally chartered bank.

Neither CGC nor any of its affiliates own shares of the Issuer for its own account. Rather, the shares reported on this Notification are owned by accounts under the discretionary investment management of one or more of the investment management companies described above

12. Date of Completion

21-Aug-2025

13. Place Of Completion

Los Angeles

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 21 August 2025

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary